4.01

1.19% -0.18

Collplant Biotechnologies Ltd (CLGN)

Overview News Price History Option Chain Discussions Forecast

Collplant Biotechnologies Ltd stock is traded at $4.01, with a volume of 4,824. It is down -1.19% in the last 24 hours and down -1.05% over the past month. CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Previous Close:

$4.19

Open:

$4.25

24h Volume:

4,824

Relative Volume:

0.43

Market Cap:

$48.11M

Revenue:

$10.96M

Net Income/Loss:

$-7.02M

P/E Ratio:

-6.3651

EPS:

-0.63

Net Cash Flow:

$-3.72M

1W Performance:

+4.02%

1M Performance:

-1.05%

6M Performance:

-34.70%

1Y Performance:

-20.38%

1-Day Range:

$4.05

$4.25

1-Week Range:

$4.00

$4.58

52-Week Range:

$3.61

$6.99

Collplant Biotechnologies Ltd Stock (CLGN) Company Profile

Name

Collplant Biotechnologies Ltd

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

Address

Employee

Twitter

@CollplantBio

Next Earnings Date

2024-11-27

Latest SEC Filings

CLGN's Discussions on Twitter

Compare CLGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLGN	4.05	48.11M	10.96M	-7.02M	-3.72M	-0.63
VRTX	467.37	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	760.78	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	564.61	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.58	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.64	24.08B	3.30B	-501.07M	1.03B	11.54

Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-23	Initiated	Alliance Global Partners	Buy

Collplant Biotechnologies Ltd Stock (CLGN) Latest News

Nov 12, 2024

CollPlant (CLGN) to Report Q3 2024 Earnings on Nov 27: Conference Call Details | CLGN Stock News - StockTitan

Nov 12, 2024

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION - Quantisnow

Nov 12, 2024

Nov 09, 2024

Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In Growth - Yahoo Finance

Nov 09, 2024

Collplant stock hits 52-week low at $3.61 amid market challenges - Investing.com Australia

Nov 09, 2024

Nov 08, 2024

500: Something went wrong - Investing.com India

Nov 08, 2024

Nov 01, 2024

Collplant stock hits 52-week low at $3.75 amid market challenges - Investing.com Australia

Nov 01, 2024

Oct 25, 2024

EF Hutton Initiates Coverage of CollPlant Biotechnologies (CLGN) with Buy Recommendation - MSN

Oct 25, 2024

Oct 23, 2024

Collplant stock hits 52-week low at $4.05 amid market challenges - Investing.com India

Oct 23, 2024

Oct 21, 2024

Collplant stock hits 52-week low at $4.05 amid market challenges By Investing.com - Investing.com South Africa

Oct 21, 2024

Oct 01, 2024

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update - Defense World

Oct 01, 2024

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 5.3% in September - MarketBeat

Oct 01, 2024

Sep 27, 2024

Benjamin F. Edwards & Company Inc. Sells 10,690 Shares of CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World

Sep 27, 2024

Sep 25, 2024

CollPlant Shareholders Approve Key Proposals - TipRanks

Sep 25, 2024

Sep 16, 2024

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Sees Large Growth in Short Interest - MarketBeat

Sep 16, 2024

3D Bioprinting Market valued at USD 1.41 billion in 2024 | ExactitudeConsultancy - GlobeNewswire

Sep 16, 2024

Sep 02, 2024

CollPlant (CLGN), Stratasys Initiate Study for Breast Implants - MSN

Sep 02, 2024

Aug 29, 2024

CollPlant and Stratasys Launch Pre-clinical Trial for Regenerative 3D-Printed Breast Implants - 3DPrint.com

Aug 29, 2024

Aug 27, 2024

The Stratasys’ Origin® printer to be tested for CollPlant’s 3D-printed breast implants - 3d adept media

Aug 27, 2024

Aug 26, 2024

HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.'s Q3 2024 Earnings (NASDAQ:CLGN) - MarketBeat

Aug 26, 2024

Head-To-Head Analysis: Envoy Medical (NASDAQ:COCH) and CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World

Aug 26, 2024

HC Wainwright Weighs in on CollPlant Biotechnologies Ltd.’s Q3 2024 Earnings (NASDAQ:CLGN) - Defense World

Aug 26, 2024

Aug 23, 2024

FY2027 EPS Estimates for CollPlant Biotechnologies Ltd. Reduced by HC Wainwright (NASDAQ:CLGN) - MarketBeat

Aug 23, 2024

HC Wainwright Research Analysts Cut Earnings Estimates for CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) - Defense World

Aug 23, 2024

Aug 22, 2024

Global Tooth Regeneration Market Size To Worth USD 8.20 Billion By 2033 | CAGR Of 6.18% - GlobeNewswire Inc.

Aug 22, 2024

CollPlant Schedules Shareholder Meeting - Investing.com India

Aug 22, 2024

Aug 21, 2024

CollPlant Schedules Shareholder Meeting By Investing.com - Investing.com Australia

Aug 21, 2024

Cracking The Code: Understanding Analyst Reviews For CollPlant Biotechnologies - Benzinga

Aug 21, 2024

CollPlant Biotechnologies’ (CLGN) Buy Rating Reaffirmed at HC Wainwright - Defense World

Aug 21, 2024

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2024 Earnings Call Transcript - Insider Monkey

Aug 21, 2024

Earnings call: CollPlant Biotechnologies reports Q2 2024 financials By Investing.com - Investing.com Australia

Aug 21, 2024